- Janice Hoppe-Spiers
- Healthcare
Agios Pharmaceuticals
Agios Pharmaceuticals launches its first wholly owned precision medicine, TIBSOVO, in record time thanks to its highly-integrated supply chain.
By Janice Hoppe-Spiers, Senior Editor at Knighthouse Publishing
Agios Pharmaceuticals specializes in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases. In addition to celebrating its 10th anniversary this year, Agios achieved another major milestone in July when it received FDA approval on TIBSOVO, the biopharmaceutical company’s first wholly owned drug, and its second approved medicine from its internal research program within the last year.